about
Longitudinal brain changes in early-onset psychosisPredictors of outcome in early-onset psychosis: a systematic reviewReduced antioxidant defense in early onset first-episode psychosis: a case-control study.Autism spectrum disorder: does neuroimaging support the DSM-5 proposal for a symptom dyad? A systematic review of functional magnetic resonance imaging and diffusion tensor imaging studies.Plasma antioxidant capacity is reduced in Asperger syndrome.Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal studyOn measuring incapacity.Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders.Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis.Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance.Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies.Olanzapine compared to quetiapine in adolescents with a first psychotic episode.Should psychiatry deal only with mental disorders without an identified medical aetiology?Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study.Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale.Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study.Psychosis induced by decreased CD4+ T cell and high viral load in human immunodeficiency virus infection: a case report.QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents.Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis.Problems with retrospective studies of the presence of schizophrenia.Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders.Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study.Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey.Regional gray matter volume deficits in adolescents with first-episode psychosis.Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.[Quetiapine treatment in adolescents: A 6-month naturalistic study].Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis.Self-perceived needs are related to violent behavior among schizophrenia outpatients.Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.Attributional style, symptomatology and awareness of illness in schizophrenia.Psychopathological sequelae of the 11 March terrorist attacks in Madrid : an epidemiological study of victims treated in a hospital.Do psychiatric patients improve their competency to consent to hospitalization after admission? A prospective study in an acute inpatient ward.Gene-environment interaction as a predictor of early adjustment in first episode psychosis.Características diferenciales de eficacia y tolerabilidad de los antipsicóticos de segunda generación en el tratamiento de trastornos psicóticos en niños y adolescentesDoes Diagnostic Classification of Early-Onset Psychosis Change Over Follow-Up?
P50
Q24643949-67AFD588-BC6F-497C-86E3-E3C306ED9520Q26859165-69750C59-2C41-4AE4-A859-46831247B695Q33820188-F0E316D2-C96A-4C13-AE07-F28A271C0862Q34024228-80050C86-6D5B-4D71-AAA2-6D4208A44397Q34245403-8ECBB71A-BA15-48AF-8139-EBAD22FF0061Q34415868-772F3AC9-D7D2-486E-B6B7-4D3F1D02B104Q36925304-49D6CF76-9C12-4D60-91EE-17C05F01F84FQ37602622-19A2F933-633B-47DF-82EF-127C340DC2D8Q37779387-A96B590D-11CC-4943-B0AB-90A4BFEE402FQ39346412-5CB651A2-70C3-4A58-8958-4F6D71F56662Q39788584-B29C1C09-0802-44E2-BCA4-3A00B1ED35F5Q41629650-2F7287A5-0A66-40A6-A3F2-073E723EC20AQ42611568-1DC092B2-5098-420A-9B12-B2BAFC863E47Q42651240-8EA9F7B1-1B03-4294-B66C-B20D4172485FQ44707420-E311DB50-FAAB-4C46-BEEB-A50527B77E08Q44808495-5863EBF6-D1E9-4A34-B24A-A508AF004276Q44937439-1B3DBB5D-7D7C-48F1-9468-FAE1134AE94CQ45391911-5B883468-4181-4BBD-A956-46AF20F1179FQ46401325-0A344473-8676-4A2C-BD78-968AF1BADA98Q46512229-89D414C7-2AE7-4F96-81FA-E01A49AE4679Q47570847-A499FD98-6725-4E6A-AC96-3223A4A108A1Q47614416-E3D14B9F-ACFD-4A01-9705-487E0BCF62AFQ47739088-B3B976B4-2794-4251-BA15-047433114FB5Q48641612-6E6013D0-11CD-49B3-B0BB-A1A1AE81A3F8Q48759046-B50F6783-B867-4ACE-94BC-1DBFC6EE0D0DQ48900458-366E7ED1-65AB-4ADE-8709-D41BEC692932Q49691146-2A219AC0-7D43-454A-B0C5-FEFFA56586E8Q50456515-0C33BD5B-258D-47CF-8AED-D5ED30594326Q50541514-F36F2D33-D484-483D-9595-06FEAC3C5FEAQ50572202-02EA42D0-A1A1-4757-A7D5-03CA1299D5C4Q50609950-A13D4888-8254-4250-B76B-15E6E7359F6CQ50632560-C5DBA32B-5CC5-4E88-9C55-60ED675A8F9FQ50788832-88607FC6-E78C-45D5-85F2-C45B912735CFQ50953838-EEAC4181-DFD4-4975-B210-1F993D59010BQ51894082-F5D2F981-0EEC-45F1-A88F-6213D93CD0B5Q51898904-DA1E4DA6-BED4-4112-972C-F046E175E8F2Q51908584-53013454-90A1-484C-A699-AE482FB97FC2Q53462518-73354A4A-56A7-447C-AC35-E3000AED3148Q58793182-E9D71533-3755-4538-9FC5-81DBF1E09E64Q58793370-862F33F4-A053-4BF6-86FB-78BFE54596E5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Fraguas
@ast
David Fraguas
@en
David Fraguas
@es
David Fraguas
@nl
David Fraguas
@sl
type
label
David Fraguas
@ast
David Fraguas
@en
David Fraguas
@es
David Fraguas
@nl
David Fraguas
@sl
prefLabel
David Fraguas
@ast
David Fraguas
@en
David Fraguas
@es
David Fraguas
@nl
David Fraguas
@sl
P106
P21
P31
P496
0000-0002-7931-2933